Michelle Patterson, MBA, PMP is the SVP of program management at Avalyn.  Ms. Patterson brings over 25 years of industry experience, spanning multiple therapeutic areas, product classes, and markets.  Most recently, she served as VP of Program Management and NASH program team leader at Intercept Pharmaceuticals where she led the resubmission of the NASH NDA. Prior to Intercept, Ms. Patterson served in senior project leadership roles at both large and small biotech companies including Novan, Roivant Sciences, GlaxoSmithKline, and Eli Lilly.

She has led six new drug applications over the last decade and has contributed to three product approvals: Taltz®, Gemtesa®, and Rapivab®.  In parallel with these major milestones, she has developed fit-for-purpose portfolio and program management processes and tools to improve the quality and reliability of delivery of drug development programs. She is widely recognized in the industry for her drug development expertise and team leadership. Ms. Patterson expertly manages the delivery of key product portfolio milestones by integrating work across multiple functions including regulatory, pre-clinical, clinical, manufacturing and product development.

Ms. Patterson earned a Bachelor of Science in biology from Cornell University and an MBA from the University of Phoenix. She is also a certified Project Management Professional.